TY - JOUR
T1 - Comparative efficacy of biologics in psoriasis
T2 - A review
AU - Kim, Iris H.
AU - West, Cameron E.
AU - Kwatra, Shawn G.
AU - Feldman, Steven R.
AU - O'Neill, Jenna L.
N1 - Funding Information:
The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, L.P. Dr Feldman has received consulting, speaking and/or grant support from Galderma Laboratories, L.P., GSK/Stiefel, Abbott Labs, Leo, Centocor, Amgen, As-tellas, Coria, Anacor, Celgene, and Aventis Pharmaceuticals, has received stock options from Photomedex, and holds stock in www.DrScore.com. Dr O’Neill, Dr West, Dr Kwatra, and Dr Kim have no conflicts of interest.
PY - 2012
Y1 - 2012
N2 - Background: Psoriasis is a chronic, immune-mediated skin disease that also has systemic manifestations. Safe and effective long-term treatments are needed. Biologic treatments that inhibit the immunopathogenesis of psoriasis have helped meet this need. Purpose: The purpose of this study was to compare the efficacy of biologic therapies used for psoriasis. Methods: A literature search was performed using PubMed and the keywords '(PASI-75 OR efficacy) AND psoriasis AND (adalimumab OR alefacept OR etanercept OR infliximab OR ustekinumab).' Randomized, double-blind, and placebo-controlled studies on US FDA-approved biologics were selected. Studies assessing the proportion of subjects achieving 75%improvement in PsoriasisArea and Severity Index (PASI-75) within a 12-week period were included. Studies on pediatric populations and psoriatic arthritis were excluded. The weighted average of PASI-75 for each reported regimen was calculated to determine the efficacy of biologic agents used for moderate-to-severe psoriasis. Tolerance and secondary efficacy measures were also examined for the selected studies. Results: FDA-approved regimens of adalimumab, infliximab, ustekinumab, and alefacept were effective in treating moderate-to-severe psoriasis. Weighted average PASI-75 scores for infliximab, ustekinumab, adalimumab, etanercept, and alefacept were 78.6%, 72.1%, 70.5%, 48.1%, and 21%, respectively. Limitations: The comparative efficacy of biologic agents data was limited to 12 weeks, thus generalizing the results to longer treatment periods may not be accurate. Conclusions: Various biologic agents for psoriasis were effective at 12 weeks in placebo-controlled trials. Available data cannot fully account for situations in clinical practice, in which combination and longer duration of therapy may be required. When choosing the most effective or best agent, multiple factors should be considered including patient preference, cost, tolerance, adverse effects, dosing schedule, andmode of administration. Adis
AB - Background: Psoriasis is a chronic, immune-mediated skin disease that also has systemic manifestations. Safe and effective long-term treatments are needed. Biologic treatments that inhibit the immunopathogenesis of psoriasis have helped meet this need. Purpose: The purpose of this study was to compare the efficacy of biologic therapies used for psoriasis. Methods: A literature search was performed using PubMed and the keywords '(PASI-75 OR efficacy) AND psoriasis AND (adalimumab OR alefacept OR etanercept OR infliximab OR ustekinumab).' Randomized, double-blind, and placebo-controlled studies on US FDA-approved biologics were selected. Studies assessing the proportion of subjects achieving 75%improvement in PsoriasisArea and Severity Index (PASI-75) within a 12-week period were included. Studies on pediatric populations and psoriatic arthritis were excluded. The weighted average of PASI-75 for each reported regimen was calculated to determine the efficacy of biologic agents used for moderate-to-severe psoriasis. Tolerance and secondary efficacy measures were also examined for the selected studies. Results: FDA-approved regimens of adalimumab, infliximab, ustekinumab, and alefacept were effective in treating moderate-to-severe psoriasis. Weighted average PASI-75 scores for infliximab, ustekinumab, adalimumab, etanercept, and alefacept were 78.6%, 72.1%, 70.5%, 48.1%, and 21%, respectively. Limitations: The comparative efficacy of biologic agents data was limited to 12 weeks, thus generalizing the results to longer treatment periods may not be accurate. Conclusions: Various biologic agents for psoriasis were effective at 12 weeks in placebo-controlled trials. Available data cannot fully account for situations in clinical practice, in which combination and longer duration of therapy may be required. When choosing the most effective or best agent, multiple factors should be considered including patient preference, cost, tolerance, adverse effects, dosing schedule, andmode of administration. Adis
KW - Adalimumab
KW - Alefacept
KW - Biological-products
KW - Etanercept
KW - Infliximab
KW - Psoriasis
KW - Ustekinumab
UR - http://www.scopus.com/inward/record.url?scp=84867424597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867424597&partnerID=8YFLogxK
U2 - 10.2165/11633110-000000000-00000
DO - 10.2165/11633110-000000000-00000
M3 - Review article
C2 - 22967166
AN - SCOPUS:84867424597
SN - 1175-0561
VL - 13
SP - 365
EP - 374
JO - American Journal of Clinical Dermatology
JF - American Journal of Clinical Dermatology
IS - 6
ER -